Xilio Therapeutics announces multiple masked T cell engager programs
Xilio Therapeutics (XLO) announced three wholly-owned preclinical programs for masked T cell engagers targeting prostate-specific membrane ...
Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday?
AbbVie Inc (NYSE:ABBV) and Xilio Therapeutics, Inc. (NASDAQ:XLO) announced a collaboration and option-to-license agreement to ...
BioWorld6d
Xilio advances masked T-cell engagers targeting PSMA, CLDN18.2 and STEAP1
Xilio Therapeutics Inc. has announced three wholly owned preclinical programs for masked T-cell engagers targeting prostate-specific membrane antigen (PSMA), claudin 18.2 (CLDN18.2) and ...
Nature11y
Intestinal epithelial apoptosis initiates gut mucosal injury during extracorporeal membrane oxygenation in the newborn piglet
Neonates and young infants exposed to extracorporeal circulation during extracorporeal membrane oxygenation ... to investigate the hypothesis that epithelial apoptosis is an early event that ...
Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs
Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with $52.0 million in upfront payments Extended ant ...